[Federal Register: May 25, 2007 (Volume 72, Number 101)]
[Notices]
[Page 29336-29337]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25my07-68]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006E-0495]
Determination of Regulatory Review Period for Purposes of Patent
Extension; KDR 401 and 403 PACEMAKERS
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for KDR 401 and 403 PACEMAKERS and is
publishing this notice of that determination as required by law. FDA
has made the determination because of the submission of an application
to the Director of Patents and Trademarks, Department of Commerce, for
the extension of a patent which claims those medical devices.
ADDRESSES: Submit written comments and petitions to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-594-2041.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
[[Page 29337]]
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For medical devices, the testing
phase begins with a clinical investigation of the device and runs until
the approval phase begins. The approval phase starts with the initial
submission of an application to market the device and continues until
permission to market the device is granted. Although only a portion of
a regulatory review period may count toward the actual amount of
extension that the Director of Patents and Trademarks may award (half
the testing phase must be subtracted as well as any time that may have
occurred before the patent was issued), FDA's determination of the
length of a regulatory review period for a medical device will include
all of the testing phase and approval phase as specified in 35 U.S.C.
156(g)(3)(B).
FDA approved for marketing the medical devices, KDR 401 and 403
PACEMAKERS. KDR 401 and 403 PACEMAKERS are indicated for the following:
Rate adaptive pacing in patients who may benefit from increased pacing
rates concurrent with increases in activity and/or minute ventilation;
accepted patient conditions warranting chronic cardiac pacing which
include: symptomatic paroxysmal or permanent second or third-degree
atrioventricular (AV) block; Symptomatic bilateral bundle branch block;
symptomatic paroxysmal or transient sinus node dysfunctions with or
without associated AV conduction disorders; bradycardia-tachycardia
syndrome to prevent symptomatic bradycardia or some forms of
symptomatic tachyarrhythmias; and vasovagal syndromes or hypersensitive
carotid sinus syndromes. KDR 401 and 403 PACEMAKERS are also indicated
for dual chamber and atrial tracking modes in patients who may benefit
from maintenance of AV synchrony. Dual chamber modes are specifically
indicated for treatment of conduction disorders that require
restoration of both rate and AV synchrony, which include: Various
degrees of AV block to maintain the atrial contribution to cardiac
output and vasovagal intolerance in the presence of persistent sinus
rhythm. Subsequent to this approval, the Patent and Trademark Office
received a patent term restoration application for KDR 401 and 403
PACEMAKERS (U.S. Patent No. 4,958,632) from Medtronic, Inc., and the
Patent and Trademark Office requested FDA's assistance in determining
this patent's eligibility for patent term restoration. In a letter
dated February 22, 2007, FDA advised the Patent and Trademark Office
that these medical devices had undergone a regulatory review period and
that the approval of KDR 401 and 403 PACEMAKERS represented the first
permitted commercial marketing or use of the products. Thereafter, the
Patent and Trademark Office requested that FDA determine the products'
regulatory review period.
FDA has determined that the applicable regulatory review period for
KDR 401 and 403 PACEMAKERS is 716 days. Of this time, 358 days occurred
during the testing phase of the regulatory review period, while 358
days occurred during the approval phase. These periods of time were
derived from the following dates:
1. The date an exemption under section 520(g) of the Federal Food,
Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) involving this
device became effective: February 16, 1996. The applicant claims that
the investigational device exemption (IDE) required under section
520(g) of the act for human tests to begin became effective on May 21,
1997. However, FDA records indicate that the IDE was determined
substantially complete for clinical studies to have begun on February
16, 1996, which represents the IDE effective date.
2. The date the application was initially submitted with respect to
the device under section 515 of the act (21 U.S.C. 360e): February 7,
1997. The applicant claims February 6, 1997, as the date the premarket
approval application (PMA) for KDR 401 and 403 PACEMAKERS (PMA 970012)
was initially submitted. However, FDA records indicate that PMA 970012
was submitted on February 7, 1997.
3. The date the application was approved: January 30, 1998. FDA has
verified the applicant's claim that PMA 970012 was approved on January
30, 1998.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 358 days of
patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Division of Dockets Management (see
ADDRESSES) written or electronic comments and ask for a redetermination
by July 24, 2007. Furthermore, any interested person may petition FDA
for a determination regarding whether the applicant for extension acted
with due diligence during the regulatory review period by November 21,
2007. To meet its burden, the petition must contain sufficient facts to
merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d
sess., pp. 41-42, 1984.) Petitions should be in the format specified in
21 CFR 10.30.
Comments and petitions should be submitted to the Division of
Dockets Management. Three copies of any mailed information are to be
submitted, except that individuals may submit one copy. Comments are to
be identified with the docket number found in brackets in the heading
of this document. Comments and petitions may be seen in the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: May 7, 2007.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. E7-10127 Filed 5-24-07; 8:45 am]
BILLING CODE 4160-01-S